
Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS)
WebsitePrice
Market cap
Next catalystExpected 1H 2027Casdozokitug + toripalimab + bevacizumab — randomized first-line uHCC · Phase 2 dataCompany release ↗
Cash
Chart & Events
Core Clinical
PreINDP2P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
PreINDP2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved / commercial
Approved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
History / paused
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved
Approved
PreINDP1P2P3FilingApproved